NCT00363714View on ClinicalTrials.gov

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Age-Related Macular DegenerationChoroidal Neovascularization
Interventions
DRUG

AGN211745

100microgram single intravitreal injection

DRUG

AGN211745

200microgram single intravitreal injection

DRUG

AGN211745

400microgram single intravitreal injection

DRUG

AGN211745

800microgram single intravitreal injection

DRUG

AGN211745

1200microgram single intravitreal injection

DRUG

AGN211745

1600microgram single intravitreal injection

Trial Locations (2)

Unknown

Baltimore

Cleveland

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

Sirna Therapeutics Inc.

INDUSTRY

lead

Allergan

INDUSTRY